HK1146242B

HK1146242B - Use of melanocortins to treat insulin sensitivity

Info

Publication number: HK1146242B
Application number: HK11100510.8A
Authority: HK
Inventors: Heather A. Halem; Michael Dewitt Culler; Andrew A. Butler
Original assignee: Ipsen Pharma S.A.S.; Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College
Priority date: 2007-11-05
Filing date: 2008-11-05
Publication date: 2016-01-29

Description

BACKGROUND OF THE INVENTION

Melanocortins are a family of regulatory peptides which are formed by post-translational processing of pro-hormone pro-opiomelanocortin (POMC; 131 amino acids in length). POMC is processed into three classes of hormones; the melanocortins, adrenocorticotropin hormone, and various endorphins (e.g. lipotropin) (Cone et al., Recent Prog. Horm. Res., 51:287-317, (1996); Cone et al., Ann. N.Y. Acad. Sci., 31:342-363, (1993)).

Five melanocortin receptors (MC-R) have been characterized to date. These include melanocyte-specific receptor (MC1-R), corticoadrenal-specific ACTH receptor (MC2-R), melacortin-3 (MC3-R), melanocortin-4 (MC4-R) and melanocortin-5 receptor (MC5-R). All of the melanocortin receptors respond to the peptide hormone class of melanocyte stimulating hormones (MSH) (Cone et al., Ann. N.Y. Acad. Sci., 680:342-363 (1993); Cone et al., Recent Prog. Horm. Res., 51:287-318 (1996)).

There has been great interest in melanocortin (MC-R) receptors as targets for the design of novel therapeutics to treat disorders of body weight such as obesity and cachexia. One of the receptors, MC4-R, is a 332 amino acid transmembrane protein expressed in brain as well as placental and gut tissues (Cone et al., Ann. N.Y. Acad. Sci., 680:342-363 (1993); Cone et al., Recent Prog. Horm. Res., 51:287-318 (1996)). Recent pharmacological confirmation has established that central MC4-R receptors are the prime mediators of the anorexic and orexigenic effects reported for melanocortin agonists and antagonists, respectively (Giraudo et al., Brain Res., 809:302-306 (1998); Farooqi et al., NE J Med., 348:1085-1095 (2003); MacNeil et al., Eu. J. Pharm., 44:141-157 (2002); MacNeil et al., Eu. J. Pharm., 450:93-109 (2002); Kask et al., NeuroReport, 10:707-711 (1999); Chen et al.,. Transgenic Res., 9:145-54, (2000); Marsh et al., Nat Genet., 21:119-22, (1999); Balthasar et al., Cell, 123:493-505 (2005)).

Complications of body weight disorders commonly include an inability to produce and utilize insulin, often resulting in faulty glucose regulation. The consequence of failure to properly control glucose metabolism affects many aspects of overall health including energy metabolism, neuropathy and heart disease. Current progress with receptor-selective melanocortin receptor ligands evidences the therapeutic potential of melanocortin receptor activation, particularly MC4-R, in the treatment of glucose regulation, including insulin metabolism.

SUMMARY OF THE INVENTION

Described herein is the use of peptides which are ligands of one or more of the melanocortin receptors (MC-R), or the pharmaceutically-acceptable salts thereof, to treat mammals suffering from insulin resistance. The ligands may be agonists to the melanocortin 4 receptor. The melanocortin receptor ligands may be selected from particular peptides described herein.

The insulin resistant subject mammals may be obese or overweight and may lose weight as a result of the administration of the peptides herein. The insulin resistant subject mammals may also be normal weight or lean. The insulin resistant condition of the subject mammals may be treated independent of weight loss. In addition, the subject mammals may be human subjects of any age, such as an infant, a child, an adult or an elderly adult.

Accordingly the present invention provides a therapeutically effective amount of a melanocortin receptor 4 agonist for use in the treatment of insulin resistance in a subject by peripheral administration wherein said melanocortin receptor 4 agonist is:

Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50;

or a pharmaceutically acceptable salt thereof. The subject may be obese, overweight, of normal weight or lean, and the obese, overweight, normal weight or lean subject may suffer from type II diabetes. The peripheral administration may be oral, subcutaneous, intraperitoneal, intramuscular, intravenous, rectal, transdermal or intranasal. The oral, subcutaneous, intraperitoneal, intramuscular, intravenous, rectal, transdermal or intranasal peripheral administration may be continuous, hourly, four times daily, three time daily, twice daily, once daily, once every other day, twice weekly, once weekly, once every two weeks, once a month, or once every two months. The peripheral administration to treat insulin resistance may also reduce the body weight of the subject.

Also described herein is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor 4 ligand described herein and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein the ligand is a compound of the formula:

Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2; SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2; SEQ ID NO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2; SEQ ID NO:4
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:5
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9
Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10
Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:12
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2; SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2; SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2; SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2; SEQ ID NO:14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2; SEQ ID NO:14
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2; SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2; SEQ ID NO:16
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2; SEQ ID NO:17
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:17
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2; SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2; SEQ ID NO:18
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2; SEQ ID NO:18
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:61
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2; SEQ ID NO:19
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2; SEQ ID NO:20
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:22
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:23
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:27
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2; SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2; SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:31
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:37
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH; SEQ ID NO:41
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH; SEQ ID NO:42
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH; SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH; SEQ ID NO:43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH; SEQ ID NO:43
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH; SEQ ID NO:42
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH; SEQ ID NO:41
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:29
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH; SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH; SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH; SEQ ID NO:45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH; SEQ ID NO:45
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH; SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH; SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH; SEQ ID NO:46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH; SEQ ID NO:46
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:47
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; SEQ ID NO:48
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:27
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:1
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:2
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2; SEQ ID NO:3
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:2
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2; SEQ ID NO:4
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2; SEQ ID NO:15
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:21
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:22
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:23
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:25
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2; SEQ ID NO:28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2; SEQ ID NO:28
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:31
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:35
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:36
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:37
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2; SEQ ID NO:16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2; SEQ ID NO:20
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:38
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:39
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40 or
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49

or pharmaceutically acceptable salts thereof.

Also described herein is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor ligand described herein and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein the ligand is a compound of the formula:

Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2; SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2; SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2; SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:54
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2; SEQ ID NO:55
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2; SEQ ID NO:55
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2; SEQ ID NO:56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2; SEQ ID NO:56
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2; SEQ ID NO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2; SEQ ID NO:57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:57 or
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2; SEQ ID NO:58

or a pharmaceutically acceptable salt thereof.

Further described herein is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor compound described herein, and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof wherein the compound is a compound of the formula:

Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2; (SEQ ID NO:60)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:158)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:160)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:161)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:176)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:178)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:180)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:182)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:184)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:185)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:194)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:196)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:198)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:202)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)55s-Gln-(Arg)3-NH2; (SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:208)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:211)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:267)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:217)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:232)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:234)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala- Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:242)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:249) Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:250)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)2-Gln-(Arg)5-NH2; (SEQ ID NO:252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:258)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-β-Ala-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(β-Ala)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2; (SEQ ID NO:264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:265) or
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2; (SEQ ID NO:266);

or pharmaceutically acceptable salts thereof.

Also described herein is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor compound described herein, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, wherein the compounds discovered to treat insulin resistance in a mammalian subject, with or without weight loss, include the following:

Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:268)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:2690)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-β-Ala-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:270) or
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2; (SEQ ID NO:270)

or pharmaceutically acceptable salts thereof.

Further described is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor compound modified with a hydantoin moiety as described herein, and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof.

Described is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor ligand described herein, pharmaceutically-acceptable salts, hydrates, solvates and/or prodrugs thereof, wherein the ligand is a compound as follows:

c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO: 271)
c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:271)
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2; (SEQ ID NO:272) or
c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2; (SEQ ID NO:272)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2; (SEQ ID NO:273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2; (SEQ ID NO:273) or
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2; (SEQ ID NO:273)
c[Hydantoin(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:274)
c[Hydantoin(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:274)
c[Hydantoin(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:274)
c[Hydantoin(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:274)
c[Hydantoin(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2; (SEQ ID NO:274)
c[Hydantoin(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2; (SEQ ID NO:275)
c[Hydantoin-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2(SEQ ID NO:275)
c[Hydantoin-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2 (SEQ ID NO:275)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2; (SEQ ID NO:276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2; (SEQ ID NO:276) or
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2, (SEQ ID NO:276)
c[Hydantoin(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2 (SEQ ID NO:277)

Also described is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor compound described herein, pharmaceutically-acceptable salts, hydrates, solvates and/or prodrugs thereof, wherein the compounds useful to treat insulin resistance in a mammalian subject, with or without weight loss, include:

Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; (SEQ ID NO:280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; (SEQ ID NO:280)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:281)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:281)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:282)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:282)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;(SEQ ID NO:280)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279) or
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:279)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
Hydantoin(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:283)
Hydantoin(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:283)
Hydantoin(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)
Hydantoin(C(O))-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:284)
Hydantoin(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)
Hydantoin(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)
Hydantoin(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)
Hydantoin(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)or
Hydantoin(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:284)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:286)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:286)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:287)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;(SEQ ID NO:287)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:288) and
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; (SEQ ID NO:288)
Hydantoin(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO:289);

or pharmaceutically acceptable salts thereof.

Also described is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor ligand belonging to a class of cyclic peptide analogs that are ligands for the melanocortin receptors as described herein, wherein the compounds useful in the treatment of insulin resistance in a mammalian subject, include the following compounds:

c[Hydantoin(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[Hydantoin(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290)
c[Hydantoin(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;(SEQ ID NO:290)
c[Hydantoin(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:290) or
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2; (SEQ ID NO:291) or
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2 (SEQ ID NO:291);

or pharmaceutically acceptable salts thereof.

Also described is a method to treat insulin resistance in a mammalian subject, with or without weight loss, by the administration of a therapeutically effective amount of a melanocortin receptor ligand described herein, wherein the ligand is a compound of the formula:

Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:293) or
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; (SEQ ID NO:292)

or pharmaceutically acceptable salts thereof.

In one instance, the compound or compounds as defined hereinabove, which are useful to treat insulin resistance in a mammalian subject, with or without weight loss, or a pharmaceutically acceptable salt thereof, are provided to said subject in need in a composition with a pharmaceutically acceptable carrier or diluent.

In one instance, the method of treating insulin resistance in a subject in need thereof, comprises peripheral administration of an effective amount of a melanocortin receptor 4 agonist to treat the insulin resistance in the subject in need thereof.

According to the invention, the melanocortin receptor 4 agonist useful to treat insulin resistance in the subject in need thereof, is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO:50) or a pharmaceutically acceptable salt thereof. In another instance described herein, the melanocortin receptor 4 agonist useful to treat insulin resistance in the subject in need thereof, is Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO:278) or a pharmaceutically acceptable salt thereof.

Administration of a compound or compostion comprising a compound or pharmaceutical salt of a compound described herein useful to treat insulin resistance, may be continuous, hourly, four times daily, three time daily, twice daily, once daily, once every other day, twice weekly, once weekly, once every two weeks, once a month, or once every two months, or longer.

The subject in need of treatment may be obese, overweight, of normal weight or lean. The obese, overweight, normal weight or lean subject may suffer from type II diabetes. Administration of a compound or compostion comprising a compound or pharmaceutical salt of a compound described herein useful to treat insulin resistance, may be peripheral administration. Examples of peripheral administration include oral, subcutaneous, intraperitoneal, intramuscular, intravenous, rectal, transdermal or intranasal forms of administration.

BRIEF DESCRIPTION OF THE DRAWINGS:

Figure 1: Food consumed in fasted rats 6 hours after administration of 100 nmole/Kg of selected compounds.
Figure 2. Effect of subcutaneous administration of 75, 300 or 600 nmole/kg/day of Compound A upon (A) body weight, (B) cumulative food intake, (C) insulin levels and (D) glucose levels in rats.
Figure 3. Effect of subcutaneous administration of 75, 300 or 600 nmole/kg/day of Compound B upon (A) body weight, (B) cumulative food intake, (C) insulin levels and (D) glucose levels in rats.
Figure 4. Effect of subcutaneous administration of 200, 600 or 1800 nmole/kg/day of Compound A upon blood glucose levels in mice.
Figure 5. Effect of intraperitoneal administration of 6.4 µmole/kg of Compound A upon blood glucose levels in obese mice.

DETAILED DESCRIPTION OF THE INVENTION

Recent studies have reported that staggering numbers of people world wide are overweight and suffering a wide variety of serious and expensive health problems. According the World Health Organization (as reported in Kouris-Blazos et al., Asia Pac. J. Clin. Nutr., 2007, 16:329-338), an estimated 1 billion people throughout the world are overweight and an estimated 300 million of these are obese. An estimated 22 million children under the age of 5 are severely overweight and in the European Union alone, the number of children who are overweight is expected to rise by 1.3 million children per year (Kosti et al., 2006, Cent. Eur. J. Public Health, 14:151-159). Obesity, as defined by the Statistical Bulletin provided by the Metropolitan Life Insurance Co., (1959, 40:1), is a condition in which a person is approximately 20-25% over normal body weight. Alternatively, an individual is considered obese if the person has a body mass index of greater than 25% over normal or greater than 30% over normal with risk factors (see Bray et al., Diabetes/Metabolism Review, 1988, 4:653-679 or Flynn et al., Proc. Nutritional Society, 1991, 50:413). One of the main causes for obesity is the consumption of a high caloric diet (Riccardi et al., Clin. Nutr., 2004, 23:447-456).

Diabetes is a chronic, debilitating disease afflicting many overweight and obese people. It is estimated that 20.8 million people in the United States alone have diabetes and more than 6 million more additional cases remain undiagnosed (Cornell, Manag. Care Pharm., 2007, 13:S11-5). Type 2 diabetes (also referred to herein as type II diabetes) is a chronic disease characterized by insulin resistance, impaired insulin secretion and hyperglycemia. Worldwide, type II diabetes is believed to affect approximately 171 million people, imparting numerous microvascular and macrovascular complications resulting in morbidity and mortality (Mudaliar, Indian J. Med. Res., 2007, 125:275-296). Mudaliar further notes that despite the availability of anti-hyperglycaemic agents available, control of glucose remains elusive in many patients.

Insulin resistance, also referred to as reduced insulin sensitivity, is a condition in which the amount of insulin needed to clear glucose from the blood of a subject is increased as compared to the amount of insulin needed to clear the same amount of glucose from the blood of a normal, non-insulin sensitive subject. Insulin resistance is regarded as the main link between obesity and type II diabetes (see Obici et al., J. Clin. Inv., 2001, 108:1079-1085 and references therein). It is known that rats fed a high fat diet show an increase in body weight (diet-induced obesity or DIO) and a decrease in insulin sensitivity. Such DIO rats provide an animal model in which to study the mechanisms of insulin resistance due to obesity (see for example Banno et al., FEBS letters, 2007, 581:1131-1136). The size and weight of adipose tissues are increased in DIO rats and it is thought that the accompanying hypertrophy of adipocytes leads to changes in the release of adipocytokines such as leptin and adiponectin which are known to regulate insulin sensitivity; it is thought that morphological changes in adipose tissue as well as changes in plasma levels of adipocytokines are among the causes of insulin resistance in DIO rats (summarized in Banno, et al., FEBS letters, 2007, 581:1131-1136 and references therein).

Melanocortins are proposed to play a large role in energy metabolism and homeostasis. Melanocortins cleaved from the POMC precursor exert their effects by binding to members of the melanocortin receptor family located in the brain. The major effect of melanocortin in the brain is to reduce food intake however, it has also been shown that melanocortin agonists or antagonists injected directly into the cerebral ventricle affect insulin actions in the periphery while food was withdrawn or while food intake was kept constant (see Schwartz et al., Nature, 2000, 404:661-671; Seeley et al., Ann. Rev. Nutr., 2004, 24:133-149; Cone et al., Recent Prog. Horm. Res., 1996, 51:287-317; Heijbor et al., Diabetologia, 2005, 48:1621-1626; Obici et al., J. Clin. Inv., 2001, 108:1079-1085). Taken together, these data suggest that central administration of melanocortins affects insulin sensitivity and may do so independently of energy balance. Banno et al., (FEBS letters, 2007, 581:1131-1136) demonstrated that intracerebral injections of a melanocortin agonist to DIO rats ameliorated insulin sensitivity in the periphery, decreased the size of and increased the number of adipocytes in white adipose tissue and decreased triglycerides content in the liver.

Considering the large numbers of overweight and/or insulin resistant subjects in need of treatment, intracerebral administration is an unlikely means to disperse medicaments to patients. There is a need in the art, therefore, to identify melanocortin agonists and antagonists suitable for peripheral administration to affect parameters of insulin action and energy metabolism such as insulin sensitivity, cellular characteristics of white adipose tissue, triglyceride levels and the like.

Nomenclature and Abbreviations

As used herein, an "obese subject" or mammal is characterized as having a body weight approximately 20% or greater than the normal body weight for said subject. Normal body weight may be determined by a comparison of the weight of the subject at a prior point in time, such as when insulin metabolism was normal, or by a comparison of the weight of the subject as compared to averages of other subjects of a similar age and/or condition.

As used herein, an "overweight subject" or mammal is characterized as having a body weight approximately 5% greater to approximately 20% greater than the normal body weight for said subject. Normal body weight may be determined by a comparison of the weight of the subject at a prior point in time, such as when insulin metabolism was normal, or by a comparison of the weight of the subject as compared to averages of other subjects of a similar age and/or condition.

As used herein, a "normal subject" or mammal is characterized as having a body weight up to approximately 5% greater than to approximately 5% less than the normal body weight for said subject. Normal body weight may be determined by a comparison of the weight of the subject at a prior point in time, such as when insulin metabolism was normal, or by a comparison of the weight of the subject as compared to averages of other subjects of a similar age and/or condition.

As used herein, a "lean subject" or mammal is characterized as having a body weight approximately 5% to 30% or even to 50% less than the normal body weight for said subject. Normal body weight may be determined by a comparison of the weight of the subject at a prior point in time, such as when insulin metabolism was normal, or by a comparison of the weight of the subject as compared to averages of other subjects of a similar age and/or condition.

As used herein, the terms "treat", "treating" and "treatment" include palliative, curative and prophylactic treatment.

As used herein, "measurable" means the biologic effect is both reproducible and significantly different from the baseline variability of the assay.

As used herein, peripherial administration includes all forms of administration of a compound or a composition comprising a compound of the instant invention which excludes intracranial administration. Examples of peripheral administration include, but are not limited to, oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, implant and the like), nasal, vaginal, rectal, sublingual or topical routes of administration, including transdermal patch applications and the like.

A "subject", as used herein and throughout this application, refers to a mammalian or non-mammalian animal including, for example and without limitation, a human, a rat, a mouse or farm animal. Reference to a subject does not necessarily indicate the presence of a disease or disorder. The term "subject" includes, for example, a mammalian or non-mammalian animal being dosed with a melanocortin analog as part of an experiment, a mammalian or non-mammalian animal being treated to help alleviate a disease or disorder, and a mammalian or non-mammalian animal being treated prophylactically to retard or prevent the onset of a disease or disorder. Subject mammals may be human subjects of any age, such as an infant, a child, an adult or an elderly adult.

A "therapeutically acceptable amount" of a compound or composition of the invention, regardless of the formulation or route of administration, is that amount which elicits a desired biological response in a subject. The biological effect of the therapeutic amount may occur at and be measured at many levels in an organism. For example, the biological effect of the therapeutic amount may occur at and be measured at the cellular level by measuring the response at a receptor which binds melanocortin and/or a melanocortin analog, or the biological effect of the therapeutic amount may occur at and be measured at the system level, such as effecting an increase/decrease in the levels of insulin. The biological effect of the therapeutic amount may occur at and be measured at the organism level, such as the alleviation of a symptom(s) or progression of a disease or condition in a subject. A therapeutically acceptable amount of a compound or composition of the invention, regardless of the formulation or route of administration, may result in one or more biological responses in a subject. In the event that the compound or composition of the invention is subject to testing in an in nitro system, a therapeutically acceptable amount of the compound or composition may be viewed as that amount which gives a measurable response in the in vitro system of choice.

The nomenclature used to define the peptides is that typically used in the art wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right. Where the amino acid has D and L isomeric forms, it is the L form of the amino acid that is represented unless otherwise explicitly indicated.

The compounds herein useful for the treatment of insulin resistance, with or without weight loss, may possess one or more chiral centers and so exist in a number of stereoisomeric forms. All stereoisomers and mixtures thereof are included in the scope of the present disclosure. Racemic compounds may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilizing methods known to those skilled in the art. In addition, chiral intermediate compounds may be resolved and used to prepare chiral compounds.

The compounds herein useful for the treatment of insulin resistance, with or without weight loss, may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included in the scope of the present disclosure. For example, 2-hydroxypyridinyl would also cover its tautomeric form, α-pyridonyl.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.


Abu	α-aminobutyric acid
Ac	acyl group
Acc
A3c	1-amino-1-cyclopropanecarboxylic acid
A4c	1-amino-1-cyclobutanecarboxylic acid
A5c	1-amino-1-cyclopentanecarboxylic acid
A6c	1-amino-1-cyclohexanecarboxylic acid
Aha	7-aminoheptanoic acid
Ahx	6-aminohexanoic acid
Aib	α-aminoisobutyric acid
Aic	2-aminoindan-2-carboxylic acid
Ala or A	alanine
β-Ala	β-alanine
Apc	denotes the structure:
Apn
Arg or R	arginine
hArg	homoarginine
Asn or N	asparagine
Asp or D	aspartic acid
Bal	3-benzothienylalanine

Bip	4,4'-biphenylalanine, represented by the structure

Bpa	4-benzoylphenylalanine
4-Br-Phe	4-bromo-phenylalanine
Cha	ß-cyclohexylalanine
hCha	homo-cyclohexylalanine
Chg	cyclohexylglycine
Cys or C	cysteine
hCys	homocysteine
Dab	2,4-diaminobutyric acid
Dap	2,3-diaminopropionic acid
Dip	β,β-diphenylalanine
Doc	8-amino-3,6-dioxaoctanoic acid with the structure of:

2-Fua	β-(2-furyl)-alanine
Gaba	4-aminobutyric acid
Gln or Q	glutamine
Glu or E	glutamic acid
Gly or G	glycine
His or H	histidine
3-Hyp
4-Hyp
Ile or I	isoleucine
Leu or L	leucine
hLeu	homoleucine
Lys or K	lysine
Met or M	methionine
β-hMet	β-homomethionine
1-Nal	β-(1-naphthyl)alanine:
2-Nal	β-(2-naphthyl)alanine
Nip	nipecotic acid
Nle	norleucine
Oic	octahydroindole-2-carboxylic acid
Orn	ornithine
2-Pal	β-(2-pyridiyl)alanine
3-Pal	β-(3-pyridiyl)alanine
4-Pal	β-(4-pyridiyl)alanine
Pen	penicillamine
Pff	(S)-pentafluorophenylalanine
Phe or F	phenylalanine
hPhe	homophenylalanine
Pro or P	proline
hPro	homoproline
Ser or S	serine
Tle	tert-Leucine
Taz	ß-(4-thiazolyl)alanine
2-Thi	ß-(2-thienyl)alanine
3-Thi	ß-(3-thienyl)alanine
Thr or T	threonine
Trp or W	tryptophan
Tyr or Y	tyrosine
D-(Et)Tyr	has a structure of

Val or V	valine

Certain other abbreviations used herein are defined as follows:
Boc Bzl:
Bzl:	benzyl
DCM:	dichloromethane
DIC:	N, N-diisopropylcarbodiimide
DIEA:	diisopropylethyl amine
Dmab:	4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino} benzyl
DMAP:	4-(dimethylamino)pyridine
DMF	dimethylformamide
DNP:	2,4-dinitrophenyl
Fm:	fluorenylmethyl
Fmoc:	fluorenylmethyloxycarbonyl
For:	formyl
HBTU:	2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
cHex	cyclohexyl
HOAT:	O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOBt:	1-hydroxy-benzotriazole
MBHA	4-methylbenzhydrylamine
Mmt:	4-methoxytrityl
NMP:	N-methylpyrrolidone
O-tBu	oxy-tert-butyl
Pbf:	2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
PyBroP	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
tBu:	tert-butyl
TIS:	triisopropylsilane
TOS:	tosyl
Trt	trityl
TFA:	trifluoro acetic acid
TFFH:	tetramethylfluoroforamidinium hexafluorophosphate
Z:	benzyloxycarbonyl

Unless otherwise indicated, with the exception of the N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids in this disclosure stand for the structure of -NH-C(R)(R')-CO-, wherein R and R' each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH₃ and R' = H for Ala), or R and R' may be joined to form a ring system.

For the N-terminal amino acid, the abbreviation stands for the structure of:

The designation "NH₂" in e.g., Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂ (SEQ ID NO:7), indicates that the C-terminus of the peptide is amidated. Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) (SEQ ID NO:36), or alternatively Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- OH (SEQ ID NO:36), indicates that the C-terminus is the free acid.

"-c(Cys-Cys)-" or "-cyclo(Cys-Cys)-" denotes the structure:

"-c(Cys-Pen)-" or "-cyclo(Cys-Pen)-" denotes the structure:

"-c(Asp-Lys)-" or "-cyclo(Asp-Lys)-" denotes the structure:

Applicants have devised the following shorthand used in naming the specific embodiments and/or species:

"HydantoinC(O)-(A^a-A^b)" denotes the structure: wherein amino acid "A^a" has the structure: and amino acid "A^b" the structure: For example, a compound represented as "c[Hydantoin(C(O)-(Cys-A^b))-A¹-A²-A³-A⁴-Cys]-" would have the following the structure: whereas a compound represented as "c[Hydantoin(C(O)-(A^b-Cys))-A¹-A²-A³ -A⁴-Cys]-" would have the structure: For further guidance, "c[Hydantoin(C(O)-(Asp-A^b))-A¹-A²-A³-A⁴-Lys]-" represents the following compound: whereas "c[Hydantoin(C(O)-(Dap-A^b))-A¹-A²-A³-A⁴-Asp]-" has the following formula:

"Acyl" refers to R"-C(O)-, where R" is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alklyaryl, and is indicated in the general formula of a particular embodiment as "Ac".

"Alkyl" refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds. The alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

"Hydroxyalkyl" refers to an alkyl group wherein one or more hydrogen atoms of the hydrocarbon group are substituted with one or more hydroxy radicals, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like.

"Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C_1-20 alkyl, wherein said -C_1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)_0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present. The presence of -(CH₂)_0-20-COOH results in the production of an alkyl acid. Non-limiting examples of alkyl acids containing, or consisting of, -(CH₂)_0-20-COOH include 2-norbornane acetic acid, tert-butyric acid, 3-cyclopentyl propionic acid, and the like.

The term "halo" encompasses fluoro, chloro, bromo and iodo.

"Heteroalkyl" refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group is replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.

"Substituted heteroalkyl" refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C_1-20 alkyl, wherein said -C_1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)_0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

"Alkenyl" refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

"Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NHCH₃, -NO₂, and -C_1-20 alkyl, wherein said -C_1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF₃, -OCH₃, -OCF₃, and -(CH₂)_0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

"Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups. Preferably, the aryl is a 5- or 6-membered ring. Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen. Non-limiting examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, 9-anthracene, and the like. Aryl substituents are selected from the group consisting of -C_1-20 alkyl, -C_1-20 alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH₂, -NO₂, -C_1-20 alkyl substituted with halogens, -CF₃, -OCF₃, and -(CH₂)_0-20-COOH. In different embodiments the aryl contains 0, 1, 2, 3, or 4 substituents.

"Alkylaryl" refers to an "alkyl" joined to an "aryl".

The term "(C₁-C₁₂)hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl and in the case of alkenyl and alkynyl there is C₂-C₁₂.

For the avoidance of doubt, unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be selected from a number of alternative groups, the selected groups may be the same or different. For the avoidance of doubt, the term independently means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.

The pharmaceutically acceptable salts of the compounds herein which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids. Examples include the HCl, HBr, HI, sulfate or bisulfate, nitrate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzene sulfonate, p-toluenesulfonate and pamoate salts. Compounds can also provide pharmaceutically acceptable metal salts, in particular non-toxic alkali and alkaline earth metal salts, with bases. Examples include the sodium, potassium, aluminum, calcium, magnesium, zinc and diethanolamine salts (Berge, S. M. et al., J. Pharm. Sci., 66:1-19 (1977); Gould, P.L., Int'l J. Pharmaceutics, 33:201-17 (1986); and Bighley, L.D. et al., Encyclo. Parma. Tech., Marcel Dekker Inc, New York, 13:453-97 (1996).

The pharmaceutically acceptable solvates of the compounds herein include the hydrates thereof. Also included within the scope of the disclosure and various salts herein are polymorphs thereof. Compounds of the disclosure therefore include compounds, their pharmaceutically acceptable salts, their solvates or polymorphs, defined in any aspect (except intermediate compounds in chemical processes).

In vitro studies

Compounds herein can be and were tested for activity as ligands of one or more of the melanocortin receptors according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the binding activities of the compounds to melanocortin receptor molecules.

Radioligand Binding Assays

Cellular membranes used for the in vitro receptor binding assays were obtained from transgenic CHO-K1 cells stably expressing hMC-R receptor subtypes 1, 3, 4 or 5. The CHO-K1 cells expressing the desired hMC-R receptor type were sonicated (Branson^® setting 7, approximately 30 sec) in ice-cold 50 mM Tris-HCl at pH 7.4 and then centrifuged at 39,000 g for 10 minutes at approximately 4°C. The pellets were resuspended in the same buffer and centrifuged at 50,000 g for 10 minutes at approximately 4°C. The washed pellets containing the cellular membranes were stored at approximately - 80°C.

Competitive inhibition of [¹²⁵I](Tyr²)-(Nle⁴-D-Phe⁷)α-MSH ([¹²⁵I]-NDP-α-MSH, Amersham Biosciences^®) binding was carried out in polypropylene 96 well plates. Cell membranes (1-10 µg protein/well) prepared as described above were incubated in 50 mM Tris-HCl at pH 7.4 containing 0.2% bovine serum albumin (BSA), 5 mM MgCh, 1 mM CaCl₂ and 0.1 mg/mL bacitracin, with increasing concentrations of the test compound and 0.1-0.3 nM [¹²⁵I]-NDP-α-MSH for approximately 90-120 minutes at approximately 37°C. Bound [¹²⁵I]-NDP-α-MSH ligand was separated from free [¹²⁵I]-NDP-α-MSH by filtration through GF/C glass fiber filter plates (Unifilter^®; Packard) presoaked with 0.1 % (w/v) polyethylenimine (PEI), using a Packard Filtermate^® harvester. Filters were washed three times with 50 mM Tris-HCl at pH 7.4 at a temperature of approximately 0-4°C and then assayed for radioactivity using a Packard Topcount^® scintillation counter. Binding data were analyzed by computer-assisted non-linear regression analysis (XL fit; IDBS). A selection of the compounds herein was tested using the above-discussed assay and the binding constants (Ki in nM) are reported in Tables 5, 6, 7 and 8.

TABLE 5 - Radioligand Binding Assay Data for Selected Compounds

Compound	Ki hMC 1-R	Ki hMC 3-R	Ki hMC4-R	Ki hMC5-R	Ki hMC1-R/ MC4-R	SEQ ID NO:
	3.87	10.1	2.09	430	1.9	SEQ ID NO:50
	4.01	12.1	1.76	352	2.3	SEQ ID NO:50
	8.29	13.3	2.78	816	3.0	SEQ ID NO:51
	3.93	172	11.0	538	0.36	SEQ ID NO:52
	1.81	20.5	4.57	502	0.4	SEQ ID NO:52
	9.67	22.0	4.2	1900	2.3	SEQ ID NO:51
	0.79	45.5	1.21	493	0.6	SEQ ID NO:53
	0.68	20.7	1.01	783	0.7	SEQ ID NO:53

Compound	Ki hMC1-R	Ki hMC 3-R	Ki hMC4-R	Ki hMC 5-R	Ki hMC1-R /MC4-R	SEQ ID NO:
114	63.9	3.07	1657	37.1	SEQ ID NO:16
11	26	7.6	1800	1.4	SEQ ID NO:7
0.05	9.3	1.1	2.9	0.0	SEQ ID NO:24
0.07	4.1	0.85	8.8	0.1	SEQ ID NO:27
0.12	10	0.43	0.42	0.3	SEQ ID NO:32
0.05	1.3	0.47	0.2	0.1	SEQ ID NO:34
0.0996	9318	0.617	10.9	0.16	SEQ ID NO:1
.0132	16.1	1.23	0.359	0.11	SEQ ID NO:2
0.207	43.2	2.58	344	0.08	SEQ ID NO:3
0.420	106	4.75	1260	0.09	SEQ ID NO:3
0.0951	9.33	0.894	13.4	0.11	SEQ ID NO:2
0.999	300	11.1	431	0.09	SEQ ID NO:4
0.106	11.8	1.49	110	0.07	SEQ ID NO:6
0.0506	9.89	1.04	16.3	0.05	SEQ ID NO:6
0.884	223	22.5	609	0.04	SEQ ID NO:11
0.721	93.5	56.0	747	0.01	SEQ ID NO:11
0.227	14.5	2.99	164	0.08	SEQ ID NO:11
0.277	25.2	3.37	203	0.08	SEQ ID NO:11
0.323	14.1	1.96	24.0	0.16	SEQ ID NO:15
34.1	118	17.0	5560	2.01	SEQ ID NO:21
29.1	22.8	3.84	2550	7.58	SEQ ID NO:22
0.442	123	10.3	521	0.04	SEQ ID NO:23
5.80	3370	583	1130	0.01	SEQ ID NO:25
0.0567	31.4	14.7	9.27	0	SEQ ID NO:24
1.68	1260	172	1220	0.01	SEQ ID NO:26
0.128	85.6	36.9	38.0	0	SEQ ID NO:26
0.352	149	3.01	339	0.12	SEQ ID NO:54
3.93	876	48.0	4940	0.08	SEQ ID NO:54
0.995	287	4.80	766	0.21	SEQ ID NO:54
0.848	184	3.76	956	0.23	SEQ ID NO:54
1.10	228	7.58	859	0.15	SEQ ID NO:54
0.659	98.9	2.55	4.19	0.26	SEQ ID NO:28
4.12	445	50.6	4300	0.08	SEQ ID NO:28
111	1710	47.7	694	2.33	SEQ ID NO:55
262	2500	96.4	1460	2.72	SEQ ID NO:55
199	5990	96.7	> 10000	2.06	SEQ ID NO:56
132	4560	40.7	8810	3.24	SEQ ID NO:56
9.12	1130	22.1	2860	0.41	SEQ ID NO:57
1.00	227	5.55	496	0.18	SEQ ID NO:57
0.536	169	3.12	358	0.17	SEQ ID NO:57
32.1	330	17.4	165	1.84	SEQ ID NO:29
10.6	41.1	7.69	54.9	1.38	SEQ ID NO:30
13.0	104	10.1	40	1.29	SEQ ID NO:30
4.28	38.5	9.0	12.5	0.48	SEQ ID NO:30
1.60	6.82	4.13	5.57	0.39	SEQ ID NO:30
12.0	85.8	11.2	40	1.07	SEQ ID NO:30
0.353	2.08	1.41	0.857	0.25	SEQ ID NO:30
0.537	86.1	5.89	2.56	0.09	SEQ ID NO:31
0.744	178	3.51	2.69	0.21	SEQ ID NO:32
0.216	17.4	0.995	0.486	0.22	SEQ ID NO:33
0.107	9.11	0.884	0.354	0.12	SEQ ID NO:33
0.148	13.9	1.06	0.423	0.14	SEQ ID NO:33
0.254	18.5	2.13	0.714	0.12	SEQ ID NO:33
0.256	29.9	1.98	0.864	0.13	SEQ ID NO:33
0.560	39.2	2.94	2.73	0.19	SEQ ID NO:33
0.186	15.2	4.93	0.537	0.04	SEQ ID NO:34
21.1	151	10.4	92.6	2.03	SEQ ID NO:35
30.7	152	15.6	114	1.97	SEQ ID NO:36
5.20	150	138	20.3	0.04	SEQ ID NO:37
4.89	290	21.3	11.1	0.23	SEQ ID NO:58
25.5	3.82	7.61	102	3.35	SEQ ID NO:16
32.5	5.85	2.53	94.6	12.85	SEQ ID NO:16
22.2	12.7	16.6	125	1.34	SEQ ID NO:20
1.17	1.56	0.277	3.24	4.22	SEQ ID NO:38
0.648	2.78	0.329	1.4	1.97	SEQ ID NO:38
0.393	1.86	0.375	1.11	1.05	SEQ ID NO:39
0.333	2.91	0.998	0.366	0.33	SEQ ID NO:39
0.461	2.45	0.931	1.37	0.50	SEQ ID NO:40
0.576	3.98	2.82	3.91	0.20	SEQ ID NO:40

Compound	Ki hMC1-R	Ki hMC 3-R	Ki hMC4-R	Ki hMC 5-R	Ki hMC1-R /MC4-R	SEQ ID NO:
17.9	1.68	0.256	23.4	69.9	SEQ ID NO:49

TABLE 6 - Radioligand Binding Assay Data for Selected Compounds

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R
	49.9	9.00	0.569	218
	11.9	38.1	5.70	11.8
	3.46	16.6	6.65	4.88
	0.614	5.09	2.31	3.23
	1.56	14.1	5.17	7.12
	1.10	1.58	6.00	0.629
	0.0868	0.751	0.0944	0.147
	1.66	4.80	0.250	9.62
	0.0452	0.298	0.169	0.386
	0.0808	0.396	0.0747	0.311
	4.41	4.23	0.455	12.9
	1.25	0.661	0.292	5.94
	1.89	0.546	0.166	6.06
	87.8	9.08	1.20	359
	124	17.8	1.11	348
	163	23.0	0.586	844
	0.144	0.352	0.0845	0.415
	1.74	0.590	0.170	4.38
	3.86	4.97	0.192	38.3
	12.8	15.9	0.950	165
	3.07	4.05	0.498	31.1
	0.792	0.570	0.162	4.18
	0.726	0.474	0.209	5.12
	0.857	0.580	0.209	4.42
	0.813	0.675	0.269	4.20
	7.84	10.2	0.783	91.8
	2.93	9.07	0.293	59.0
	2.42	6.56	0.238	41.7
	6.66	19.3	0.819	88.8
	2.63	2.09	0.0737	11.6
	2.48	1.21	0.209	9.17
	3.65	2.26	0.261	12.1
	7.32	11.0	0.659	78.0
	4.11	7.26	0.302	48.3
	6.77	14.3	0.781	84.0
	3.04	3.22	0.230	3.85
	3.24	2.66	0.208	5.96
	1.58	1.43	0.275	2.97
	4.59	6.28	0.588	22.6
	6.46	5.22	0.380	15.3
	4.62	5.68	0.505	45.3
	2.12	3.99	0.352	27.5
	3.41	0.975	0.549	11.3
	4.18	1.12	0.223	15.3
	2.71	0.732	0.202	5.53
	5.66	1.40	0.446	6.23
	0.211	0.665	0.635	118
	0.351	0.891	0.503	102
	0.209	0.699	0.596	137
	0.439	1.52	0.476	115
	0.821	2.50	0.700	148
	0.406	1.11	0.602	131
	1.27	4.63	1.51	220

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R
2058	113	10.7	239
1818	306	5.87	979
1.75	1.74	0.15	16.8
1.50	1.61	0.301	10.4
1.81	2.08	0.305	19.3
2.69	2.59	0.243	19.2
2.25	0.62	0.303	2.77
1.49	0.604	0.865	3.13
3.28	1.95	0.575	15.5
2.24	1.57	0.437	16.4
2.14	1.12	0.624	11.9
2.50	1.59	0.573	15.7
3.00	1.70	0.442	15.5
4.29	2.15	0.425	15.5
0.410	0.837	0.246	56.3
0.572	1.07	0.210	63.6
0.475	0.800	0.196	53.8
0.779	1.21	0.293	56.0
0.212	1.23	0.484	58.5
0.778	1.22	0.468	47.0

TABLE 7 - Binding Constants for Formula (V) Examples

Formula (V) Compounds	Ki hMC1	Ki hMC3	Ki hMC4	Ki hMC5
230	7590	126	7020
72.6	1920	45.2	>10000
60.4	2840	52.4	>10000
28	90.5	12.7	877
16.4	863	4.97	>10000
37.7	576	7.81	6400
66.6	1820	19.9	>10000
200	68.8	6.63	142
9028	2628	35.8	1156
9938	2390	44.6	1103
2170	1479	16.5	451
1276	2756	266	1096
7567	1922	420	2879

Formula (VI) Compounds	Ki hMC1	Ki hMC3	Ki hMC4	Ki hMC5
14.3	198	5.76	67.8
11.9	311	5.41	73.9
31.6	224	19.6	2500
16.0	63.9	8.64	1820
33.7	132	40.2	3210
48.3	534	74.1	3290
40.8	870	137	3560
17.7	73.6	8.40	2120
7.92	46.4	6.70	21.3
20.9	69.7	8.32	50.0
12.9	38.5	3.53	27.1
127	811	10.4	381
13.9	38.4	5.73	18.9
11.7	73.1	4.28	34.7
36.8	290	13.7	133
15.3	160	8.66	33.4
11.6	194	11.5	28.9
19.3	331	26.7	44.6
9.49	124	2.95	2260
4.30	78.0	1.77	4540
8.59	94.1	2.44	7760
5.68	55.5	2.44	4220
2.65	41.3	4.17	650
3.52	48.7	5.78	872
3.51	29.2	6.04	914
1.14	01.7	4.53	783
11.9	7.43	0.195	14.6

Formula (VII) Compounds	Ki hMC1	Ki hMC3	Ki hMC4	Ki hMC5
47.6	1100	47.1	>10000
21.2	730	34.5	>10000
47.4	1550	27.9	>10000
53.4	1760	41.6	>10000
38.5	1760	53.2	9270
15.6	305	8.92	3070

Compound	Ki hMC1-R	Ki hMC3-R	Ki hMC4-R	Ki hMC5-R
8.53	21.2	3.72	714
6.09	34.9	2.02	864
6.27	36.4	1.53	888
1.48	14.8	2.34	491
4.7	42	2.25	1470
0.323	1.33	1.95	786

Melanocortin Functional Activity and Selectivity

The compounds described herein will interact preferentially (i.e., selectively) to MC-4 relative to the other melanocortin receptors. Selectivity is particularly important when the compounds are administered to humans or other animals to minimize the number of side effects associated with their administration. MC-4 selectivity of a compound is defined herein as the ratio of the EC₅₀ of the compound for an MC-1 receptor (EC₅₀ -MC-1) over the EC₅₀ of the compound for the MC-3 (EC₅₀ -MC-3)/MC-4 (EC₅₀ -MC-4) receptor, the EC₅₀ values being measured as described above. The formulas are as follows: A compound is defined herein as being "selective for the MC-3 receptor" when the above mentioned ratio "MC-3-selectivity" is at least about 10, preferably at least about 100, and more preferably at least about 500.

A compound is defined herein as being "selective for the MC-4 receptor" when the above mentioned ratio "MC-4-selectivity" is at least about 10, preferably at least about 100, and more preferably at least about 500.

One skilled in the art would know that procedures similar to those described herein may be used to assay the binding activities of the compounds to melanocortin receptor molecules.

cyclic AMP Bioassay

Intracellular cyclic AMP (cAMP) levels were determined by an electrochemiluminescence (ECL) assay (Meso Scale Discovery^®, Gaithersburg, MD; referred to hereinafter as MSD). CHO-K1 cells stably expressing the hMC receptor subtypes were suspended in RMPI 1640^® assay buffer (RMPI 1640 buffer contains 0.5 mM isobutylmethylxanthine (IBMX), and 0.2% protein cocktail (MSD blocker A)). Transgenic CHO-K1 cells stably expressing hMC receptor subtypes 1, 3, 4 or 5 were dispensed at a density of approximately 7,000 cells/well in 384-well Multi-Array^® plates (MSD) containing integrated carbon electrodes and coated with anti-cAMP antibody. Increasing concentrations of the test compounds were added and the cells were incubated for approximately 40 minutes at approximately 37°C. Following this incubation, lysis buffer (HEPES-buffered saline solution with MgCh and Triton X-100^® at ph 7.3) containing 0.2% protein cocktail and 2.5 nM TAG™ ruthenium-labeled cAMP (MSD) was added and the cells were incubated for approximately 90 minutes at room temperature. At the end of the second incubation period read buffer (Tris-buffered solution containing an ECL co-reactant and Triton X-100 at ph 7.8) was added and the cAMP levels in the cell lysates were immediately determined by ECL detection with a Sector Imager 6000 reader^® (MSD). Data were analyzed using a computer-assisted non-linear regression analysis (XL fit; IDBS) and reported as either an EC₅₀ value or a Kb value.

EC₅₀ represents the concentration of an agonist compound needed to obtain 50% of the maximum reaction response, e.g., 50% of the maximum level of cAMP as determined using the assay described above. The Kb value reflects the potency of an antagonist and is determined by Schild analysis. In brief, concentration-response curves of an agonist are carried out in the presence of increasing concentrations of an antagonist. The Kb value is the concentration of antagonist which would produce a 2-fold shift in the concentration-response curve for an agonist. It is calculated by extrapolating the line on a Schild plot to zero on the y-axis.

A selection of compounds was tested using the above-discussed assays and the results are reported in Tables 9, 10, 11, and 12.

TABLE 9 - cAMP Bioassay Data for Selected Compounds

Compound						SEQ ID NO:
	5.79	5.25	0.313	1630	18.0	SEQ ID NO:50
	6.17	5.6	0.397	1020	16.0	SEQ ID NO:50
	26.5	10.5	0.493	2440	54.0	SEQ ID NO:51
	8.43	32.4	0.959	2140	9.0	SEQ ID NO:52
	4.23	8.09	0.719	23.2	6.0	SEQ ID NO:52
	48.3	13.3	0.79	10000	61.0	SEQ ID NO:51
	1.48	5.76	0.078	297	19.0	SEQ ID NO:53
	1.39	2.89	0.055	467	25.0	SEQ ID NO:53

ND = not determined

Compound						SEQ ID NO:
	2.4	0.33	0.078	420	31	SEQ ID NO:7
	0.35	1.1	0.11	0.37	3	SEQ ID NO:24
	0.31	0.27	0.018	3.1	17	SEQ ID NO:27
	0.28	0.24	0.028	3.9	10	SEQ ID NO:32
	0.37	0.1	0.021	1.7	18	SEQ ID NO:34
	0.834	0.145	0.128	2.79	6.52	SEQ ID NO:1
	0.76	0.199	0.0492	1.73	15.45	SEQ ID NO:2
	3.26	0.189	0.0949	30.2	34.35	SEQ ID NO:6
	1.37	0.628	0.131	3.48	10.46	SEQ ID NO:6
	2.27	3.32	7.24	415	0.31	SEQ ID NO:11
	ND	1.89	0.531	ND	ND	SEQ ID NO:21
	14.3	2.03	0.183	2240	78.14	SEQ ID NO:22
	0.345	2.71	5376	2.38	0.06	SEQ ID NO:24
	0.685	81.8	86.9	31.8	0.01	SEQ ID NO:26
	0.931	3.22	1.65	>10000	0.56	SEQ ID NO:28
	3.24	0.465	0.0915	78.5	35.41	SEQ ID NO:30
	0.819	0.541	0.453	45.3	1.81	SEQ ID NO:30

ND = not determined

Compound	EC50 hMC 1-R	Kb hMC3-R	Kb MC4-R	EC50 hMC5-R	SEQ ID NO:
	17.6	12.4	38.8	11.8	SEQ ID NO:16
	0.619	2.98	0.109	0.189	SEQ ID NO:38
	0.913	0.536	0.346	0.489	SEQ ID NO:38
	0.231	18.4	0.782	0.153	SEQ ID NO:39
	0.581	10.8	0.967	0.126	SEQ ID NO:39
	0.413	9.32	0.824	0.307	SEQ ID NO:40
	1.27	3.02	0.442	0.736	SEQ ID NO:40
	383	61.5	53.6	2842	SEQ ID NO:16

Compound	EC50 hMC 1-R	Kb hMC3-R	Kb MC4-R	EC50 hMC5-R	SEQ ID NO:
193	5.72	1.58	1111	SEQ ID NO:49

Compound		Kb hMC3-R	Kb hMC4-R
	66.1	33.4	0.687	6.84
	ND	4500	105	ND
	ND	395	16.8	ND
	ND	207	18.5	ND
	ND	220	4.07	ND
	ND	261	3.11	ND
	ND	14.1	22.8	ND
	ND	233	26.0	ND
	1.39	16.2	7.94	0.839
	3.65	19.4	3.73	1.61
	ND	17.7	1.49	ND
	6.3	70.0	1.66	38.2
	12.1	30.3	1.81	70.0
	33.6	140	12.2	66.9
	269	105	5.92	104
	690	70.7	4.56	177
	3.23	8.97	4.61	2.86
	52.0	170	6.14	328
	146	104	32.0	1400
	114	44.6	28.4	879
	67.1	439	46.5	582
	144	116	8.93	819
	36.0	46.5	11.4	56.1
	93.0	71	15.9	> 10000
	39.7	30.9	6.66	501
	35.2	22.9	12.6	199
	29.1	13.6	13.4	204
	86.1	41.7	19.4	2360
	38.3	20.2	21.2	> 10000
	68.6	153	33.2	> 10000
	70.4	286	18.6	> 10000
	33.1	65.1	15.3	1720
	88.2	10.6	17.4	514
	58.7	39.3	10.3	460
	45.4	12.7	12.7	162
	309	22.8	17.1	570
	7.86	10.5	0.843	4900
	29.7	25.6	7.37	82.9
	15.2	14.6	4.52	36.8
	6.7	9.38	11.7	46.2
	7.9	41.7	10.9	62.4
	16.9	36.0	7.12	58.9
	16.4	20.8	7.31	44.2
	12.0	13.7	9.38	54.2
	7.5	12.2	7.61	51.7
	43.3	215	5.87	1286
	37.9	112	41.1	1798

ND = not determined


4.70	4.56	0.634	147
5.90	7.73	1.02	2890
0.481	7.32	0.964	2010
7.15	9.37	1.25	1570


ND	ND	ND	ND
770	221	4.52	869
29	22.6	16.7	173
102	26.3	14.6	261
26.6	101	9.34	351
45.5	181	6.35	149
23.7	9.22	5.87	39.7
34.7	15.0	8.68	28.2
19.1	106	4.59	100
19.8	37.8	8.43	158
11.2	52.1	9.45	95.7
33.8	93.6	4.42	89.5
232	68.8	10.0	250
32.2	98.3	5.23	194

ND = not determined


5.66	4.70	0.422	1551
7.57	4.18	0.600	1792
2.36	2.74	0.260	500
2.81	3.29	0.298	566
1.86	1.39	0.367	165
2.06	1.61	0.394	199

TABLE 11 - Intracellular Cyclic AMP (cAMP) Levels for Formula (I) Examples

Formula (V) Compounds
-	218	5.42	-
-	22.3	3.62	-
-	39.2	4.94	-
56.7	18.2	0.182	>10000
56.6	88.6	4.50	9300
-	49.3	2.12	-

Formula (VI) Compounds
54.3	12.2	0.177	>10000
124	8.05	0.214	>10000
-	4.89	1.80	-
-	2.56	1.47	-
-	4.61	0.977	-
-	9.68	1.83	-
-	9.97	13.9	-
14.2	2.46	0.336	201
17.0	21.5	0.584	352
40.2	8.90	0.495	8300
17.6	2.23	0.241	516
4.70	2.22	0.309	355
18.0	17.1	0.160	2710
12.9	10.3	0.125	7440
8.83	7.86	0.0979	4010
9.97	3.63	0.0687	335
8.81	18.2	0.503	3560
11.5	23.2	0.513	3950
7.53	11.6	0.435	9840
8.85	5.17	0.599	3610
96.6	13.1	21.2	103

Formula (VII) Compounds
-	6.28	0.407	-
-	3.77	0.214	-
-	4.72	0.428	-
-	8.51	1.85	-
-	5.66	1.72	-
14.5	21.8	0.576	1780

Compound
6.42	2.39	0.194	1540
9.66	6.11	0.275	1730
8.67	4.21	0.363	1320
5.78	3.95	0.219	2580

In vivo studies

Compounds herein can be and were tested for an effect upon insulin resistance and/or body weight according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the effect of the compounds upon insulin resistance and/or body weight.

Ligand compounds activating melanocortin receptors tested in the in vivo studies were as follows (Table 13):

Ligand Code	Structure
Compound A
Compound B

Acute feeding experiments (fasting)

Male Sprague Dawley rats (250g) were housed in individual cages and maintained under 12:12 hour light:dark conditions. The rats were fasted for 18 hours prior to the start of the experiment with water available ad libitum. At time 0, the rats were injected subcutaneously (sc) with selected compounds at doses of 100 nmole/kg, or with vehicle, and were provided with food. Individual food consumption was measured at about 2, 4 and 6 hours after injection. Data for selected compounds are reported in Figure 1.

Chronic feeding experiments

Male, Sprague Dawley rats that had been fed either a normal diet (300g; Research Diets 12450) or a high fat diet (400g; Research Diets 12451) for 10 weeks prior to the start of the experiment were housed in individual cages and maintained under 12:12 hour light:dark conditions with both food and water available ad libitum. The rats were anesthetized and implanted subcutaneously with an osmotic mini pump (Alzet, Cupertino, CA). The pumps delivered either Compound A or Compound B at doses of 75, 300 or 1200 nmole/kg/day, or vehicle for 7 days. Individual body weight and food consumption were measured daily.

On day 7 rats were anesthetized and fit with a jugular-right atrial cannula. On day 8 an iv glucose tolerance test was performed and blood samples were withdrawn into heparinized syringes at time -10 and 0. Immediately after the time 0 blood sample, the rats were injected with glucose (1g/kg) via the indwelling cannula. Subsequent blood samples were withdrawn at 2.5, 5, 10, 20 and 40 minutes later. Plasma levels of glucose (Diagnostic Chemicals Limited) and insulin (Alpco) were determined by commercially available kits. Results are showin in Figures 2A-D and 3A-D.

Glucose tolerance tests

Male, C57BL/6 mice that had been fed either a normal diet (30g; Research Diets 12450) or a high fat diet (45g; Research Diets 12452) for 12 weeks prior to the start of the experiment were housed in individual cages and maintained under 12:12 hour light:dark conditions with both food and water available ad libitum. The mice were anesthetized and implanted subcutaneously with an osmotic mini pump (Alzet, Cupertino, CA). The pumps delivered Compound A at doses of 200, 600 or 1800 nmole/kg/day, or vehicle for 14 days. On day 14 the mice were fasted for 18 hours or overnight. On day 15 an glucose tolerance test was performed by injecting the mice with glucose (2g/kg) ip. Blood samples were taken by tail stick at 0, 15, 30, 60 and 180 minutes after the glucose injection and blood glucose level was measured using an Accu-Chek glucometer. Results are shown in Figure 4.

Male, Lep^ob/Lep^ob mice (50g) were group housed maintained under 12:12 hour light:dark conditions with both food and water available ad libitum. The mice were fasted for 18 hours or overnight and an ip glucose tolerance test was performed. Mice were injected with Compound A ip at a dose of 6.4µmole/kg at -15 minutes and a blood sample was taken by tail stick. At time 0 mice were injected ip with glucose (1g/kg) and blood samples were taken by tail stick at 0, 15, 30, 60 and 90 minutes later and blood glucose level was measured using Glucometer Elite XL (Bayer Corporation). Results are shown in Figure 5.

Administration and Use

The peptides herein can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methane sulfonic, toluene sulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide oherein is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide herein (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax^®, 300 SB, C-8). The column is eluted with: (1) 0.1N ammonium acetate aqueous solution for 0.5 hours; (2) 0.25N acetic acid aqueous solution for 0.5 hours; and (3) a linear gradient (20% to 100% of solution B over 30 minutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness.

As is well known to those skilled in the art, the known and potential uses of peptides with melanocortin receptor (MC-R) agonist or antagonist activity is varied and multitudinous, thus the administration of the compounds herein for purposes of eliciting an agonist effect can have the same effects and uses as melanocortin itself.

Accordingly, the present disclosure includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds herein in association with a pharmaceutically acceptable carrier.

The dosage of active ingredient in the compositions herein may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities described herein is in the range of 1x10^-7 to 200 mg/kg/day, preferably 1x10^-4 to 100 mg/kg/day which can be administered as a single dose or divided into multiple doses.

The compounds herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations described herein for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

Further, a compound herein can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Patent No. 5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. The teachings of the foregoing patents and applications are incorporated herein by reference.

SEQUENCE LISTING

<110> SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURE AND MECHANICAL COLLEGE Halem, Heather Culler, Michael Butler, Andrew
<120> USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
<130> 183P/PCT2
<150> US 61/001933 <151> 2007-11-05
<160> 293
<170> PatentIn version 3.5
<210> 1 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala or 1-amino-1-cyclohexanecarboxylic acid (Ac)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 1
<210> 2 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 6-aminohexanoic acid (Ahx) or 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 2
<210> 3 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa=D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 3
<210> 4 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 4
<210> 5 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = 1-amino-1-cyclohexanecarboxylic acid (A6c) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 5
<210> 6 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal), beta-cyclohexylAla (Cha) or Nle, all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 6
<210> 7 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 7
<210> 8 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 8
<210> 9 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or Gly
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 9
<210> 10 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> xaa = D-Cys
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba) or alpha-aminoisobutyric acid (Aib)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 10
<210> 11 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC FEATURE <222> (1)..(1) <223> Xaa = octahydroindole-2-carboxylic acid (oic), cyclohexylGly (Chg), homo-cyclohexylAla (hcha), D-Cha,nipecotic acid (Nip), hPro, hLeu, Phe, D-Phe, D-Chg, hPhe, beta-homoMet, or 4-aminobutyric acid (Gaba), all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 11
<210> 12 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = beta-cyclohexylAla (Cha) modified with n-butanoyl
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 12
<210> 13 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = beta-cyclohexylAla (Cha), homo-cyclohexylAla (hCha), Leu, homo-Leu (hLeu) or Phe, all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 13
<210> 14 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), 7-aminoheptanoic acid (Aha) or 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 14
<210> 15 <211> 8 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn), 4-aminobutyric acid (Gaba), 6-aminohexanoic acid (Ahx), beta-Ala, or D-Ala
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 15
<210> 16 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Trp, beta-(2-naphthyl)Ala (2-Nal) or beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 16
<210> 17 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with n-butanoyl
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or Trp
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 17
<210> 18 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylAla (Bal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 18
<210> 19 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = D-Ala
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 19
<210> 20 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-beta-2-naphthylAla (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 20
<210> 21 <211> 8 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 21
<210> 22 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = Cys or penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 22
<210> 23 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 23
<210> 24 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = Arg or homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 24
<210> 25 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 25
<210> 26 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe or D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 26
<210> 27 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa= Nle
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 27
<210> 28 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Trp or 3-benzothienylAla (Bal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 28
<210> 29 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen) or Cys
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 29
<210> 30 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-alpha-aminobutyric acid (D-Abu), D-val, D-Ile, D-Leu, D-tert-Leu (D-Tle) or D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 30
<210> 31 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 31
<210> 32 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = Cys or penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 32
<210> 33 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Leu, beta-cyclohexylAla (Cha), Ile, Phe, val or beta-(2-naphthyl)Ala (2-Nal), all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 33
<210> 34 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle or Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 34
<210> 35 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = beta-(3-pyridiyl)Ala (3-Pal)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 35
<210> 36 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 36
<210> 37 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 37
<210> 38 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Ala or beta-Ala
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 38
<210> 39 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba) or 6-aminohexanoic acid (Ahx)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 39
<210> 40 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-Phe (hPhe) or beta-cyclohexylAla (Cha), both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 40
<210> 41 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala or 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 41
<210> 42 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 6-aminohexanoic acid (Ahx) or 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 42
<210> 43 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MOD_RES <222> (9)..(9) <223> C-terminus is the free acid
<400> 43
<210> 44 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = beta-cyclohexylAla (Cha), Nle, cyclohexylGly (chg), D-Cha, homo-cyclohexylAla (hcha), D-Chg or homo-Phe (hPhe), all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 44
<210> 45 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba), 6-aminohexanoic acid (Ahx), beta-Ala or D-Ala
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 45
<210> 46 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Trp, beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylalanine (Bal)
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 46
<210> 47 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 47
<210> 48 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (8)..(8) <223> C-terminus is the free acid
<400> 48
<210> 49 <211> 8 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 49
<210> 50 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Arg or D-Arg, both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 50
<210> 51 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Arg or Arg, both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 51
<210> 52 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Arg or Arg, both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 52
<210> 53 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Arg or Arg, both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 53
<210> 54 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(9) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = Gly, D-Ala, beta-Ala, 4-aminobutyric acid (Gaba) or 5-aminopentanoic acid (Apn)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 54
<210> 55 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = Trp or beta-(2-naphthyl)alanine (2-Nal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 55
<210> 56 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = Trp or beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 56
<210> 57 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(9) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = Ala, beta-Ala or 4-aminobutyric acid (Gaba)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 57
<210> 58 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(9) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 58
<210> 59 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> Cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Glu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 59
<210> 60 <211> 18 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (12)..(12) <223> Xaa = Nle
<220> <221> DOMAIN <222> (13)..(18) <223> cyclic
<220> <221> MISC_FEATURE <222> (15)..(15) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 60
<210> 61 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (12)..(12) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = Nle
<220> <221> DOMAIN <222> (14)..(19) <223> cyclic
<220> <221> MISC_FEATURE <222> (16)..(16) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 61
<210> 62 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle or Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 62
<210> 63 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 63
<210> 64 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 64
<210> 65 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 65
<210> 66 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 66
<210> 67 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (12)..(12) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 67
<210> 68 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 68
<210> 69 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala or 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 69
<210> 70 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 70
<210> 71 <211> 24 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 71
<210> 72 <211> 22 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 72
<210> 73 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 73
<210> 74 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 74
<210> 75 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 75
<210> 76 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 76
<210> 77 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 77
<210> 78 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 78
<210> 79 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (15)..(15) <223> Xaa = alpha-aminoisobutyric acid (Aib)
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 79
<210> 80 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Arg or Lys
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 80
<210> 81 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal) or beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 81
<210> 82 <211> 22 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Arg or Lys
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 82
<210> 83 <211> 23 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Arg or Lys
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 83
<210> 84 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 84
<210> 85 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 85
<210> 86 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 86
<210> 87 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 87
<210> 88 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal) or beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 88
<210> 89 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 89
<210> 90 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 90
<210> 91 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 91
<210> 92 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 92
<210> 93 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 93
<210> 94 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 94
<210> 95 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 95
<210> 96 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 96
<210> 97 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 97
<210> 98 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 98
<210> 99 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 99
<210> 100 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 100
<210> 101 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 101
<210> 102 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (AC)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 102
<210> 103 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (AC)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 103
<210> 104 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (AC)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 104
<210> 105 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 105
<210> 106 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 106
<210> 107 <211> 24 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 107
<210> 108 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 108
<210> 109 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 109
<210> 110 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 110
<210> 111 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 111
<210> 112 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 112
<210> 113 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 113
<210> 114 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 114
<210> 115 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 115
<210> 116 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 116
<210> 117 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 117
<210> 118 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 118
<210> 119 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 119
<210> 120 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 120
<210> 121 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 121
<210> 122 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(1-naphthyl)Ala (1-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 122
<210> 123 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 123
<210> 124 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 124
<210> 125 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 125
<210> 126 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 126
<210> 127 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 127
<210> 128 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 128
<210> 129 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 129
<210> 130 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 130
<210> 131 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 131
<210> 132 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 132
<210> 133 <211> 24 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (24)..(24) <223> AMIDATION
<400> 133
<210> 134 <211> 25 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 134
<210> 135 <211> 25 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 3-benzothienylAla (Bal)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Lys or Arg
<220> <221> MISC_FEATURE <222> (13)..(13) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (25)..(25) <223> AMIDATION
<400> 135
<210> 136 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 136
<210> 137 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 137
<210> 138 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 138
<210> 139 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 139
<210> 140 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 140
<210> 141 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 141
<210> 142 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 142
<210> 143 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 143
<210> 144 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 144
<210> 145 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 145
<210> 146 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 146
<210> 147 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 147
<210> 148 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 148
<210> 149 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 149
<210> 150 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 150
<210> 151 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 151
<210> 152 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 152
<210> 153 <211> 21 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 153
<210> 154 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 154
<210> 155 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 155
<210> 156 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (AC)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 156
<210> 157 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 157
<210> 158 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9) .. (10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 158
<210> 159 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 159
<210> 160 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9) .. (9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 160
<210> 161 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 161
<210> 162 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 162
<210> 163 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 163
<210> 164 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 164
<210> 165 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 165
<210> 166 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 166
<210> 167 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 167
<210> 168 <211> 18 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 168
<210> 169 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = Gly or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 169
<210> 170 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 170
<210> 171 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 171
<210> 172 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 172
<210> 173 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 173
<210> 174 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 174
<210> 175 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 175
<210> 176 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 176
<210> 177 <211> 20 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 6-aminohexanoic acid (Ahx)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 177
<210> 178 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 6-aminohexanoic acid (Ahx)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 178
<210> 179 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 179
<210> 180 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 180
<210> 181 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 181
<210> 182 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 182
<210> 183 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = beta-cyclohexylAla (Cha), homo-cyclohexylAla (hcha), or Nle, all modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 183
<210> 184 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = beta-cyclohexylAla (Cha) or homo-cyclohexylAla (hcha), both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 184
<210> 185 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle or cyclohexylGly (Chg), both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 185
<210> 186 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = cyclohexylGly (Chg) or homo-cyclohexylAla (hcha), both modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 186
<210> 187 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9) .. (10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 187
<210> 188 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 188
<210> 189 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 189
<210> 190 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-cyclohexylAla (hCha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 190
<210> 191 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 191
<210> 192 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 192
<210> 193 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 193
<210> 194 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = homo-cyclohexylAla (hcha) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 194
<210> 195 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-cyclohexylGly (D-Chg) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 195
<210> 196 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-cyclohexylGly (D-Chg) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC FEATURE <222> (7) .. (7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 196
<210> 197 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = homo-phenylAla (hPhe) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 197
<210> 198 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = homo-phenylAla (hPhe) modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 198
<210> 199 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn) or 6-aminohexanoic acid (Ahx)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 199
<210> 200 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn) or 6-aminohexanoic acid (Ahx)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 200
<210> 201 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 201
<210> 202 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Trp
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 202
<210> 203 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 203
<210> 204 <211> 21 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 204
<210> 205 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 205
<210> 206 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 206
<210> 207 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9) .. (9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 207
<210> 208 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (AC)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = penicillamine (Pen)
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 208
<210> 209 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 209
<210> 210 <211> 18 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (18)..(18) <223> AMIDATION
<400> 210
<210> 211 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 211
<210> 212 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 212
<210> 213 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Gly or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 213
<210> 214 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 214
<210> 215 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = Tyr or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 215
<210> 216 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 216
<210> 217 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 217
<210> 218 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 218
<210> 219 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 219
<210> 220 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 220
<210> 221 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 221
<210> 222 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 222
<210> 223 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 223
<210> 224 <211> 23 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (23)..(23) <223> AMIDATION
<400> 224
<210> 225 <211> 21 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 225
<210> 226 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 226
<210> 227 <211> 22 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 227
<210> 228 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 228
<210> 229 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 229
<210> 230 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 230
<210> 231 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10) .. (11) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 231
<210> 232 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = homo-Arg (hArg)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = 4,4'-biphenylAla (Bip)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (11)..(11) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 232
<210> 233 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 233
<210> 234 <211> 19 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (3) .. (3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 234
<210> 235 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 235
<210> 236 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 236
<210> 237 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9) .. (9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 237
<210> 238 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 238
<210> 239 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 239
<210> 240 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 240
<210> 241 <211> 22 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 241
<210> 242 <211> 20 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 5-aminopentanoic acid (Apn)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 242
<210> 243 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2) .. (8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 243
<210> 244 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 244
<210> 245 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 245
<210> 246 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 246
<210> 247 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 247
<210> 248 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5) .. (5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10) .. (10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 248
<210> 249 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 249
<210> 250 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Leu
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 250
<210> 251 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1) .. (1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 251
<210> 252 <211> 19 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (AC)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 252
<210> 253 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 253
<210> 254 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 254
<210> 255 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 255
<210> 256 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 256
<210> 257 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 257
<210> 258 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle modified with acyl (Ac)
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-cyclohexylAla (D-Cha)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 258
<210> 259 <211> 21 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 259
<210> 260 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 260
<210> 261 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 261
<210> 262 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = beta-Ala or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 262
<210> 263 <211> 21 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (21)..(21) <223> AMIDATION
<400> 263
<210> 264 <211> 19 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (19)..(19) <223> AMIDATION
<400> 264
<210> 265 <211> 22 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (DOC)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (22)..(22) <223> AMIDATION
<400> 265
<210> 266 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Nle
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = 4-aminobutyric acid (Gaba)
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
<220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc) or absent
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 266
<210> 267 <211> 20 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Phe
<220> <221> DOMAIN <222> (2)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-(Et)Tyr
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala
<220> <221> MISC_FEATURE <222> (8)..(8) <223> Xaa = D-Cys
<220> <221> MISC_FEATURE <222> (9)..(10) <223> Xaa = beta-Ala
<220> <221> MOD_RES <222> (20)..(20) <223> AMIDATION
<400> 267
<210> 268 <211> 12 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (AC)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-4-bromo-phenylAla (D-4-Br-Phe)
<220> <221> MOD_RES <222> (12)..(12) <223> AMIDATION
<400> 268
<210> 269 <211> 12 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (Ac)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = Trp, beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylAla (Bal)
<220> <221> MOD_RES <222> (12)..(12) <223> AMIDATION
<400> 269
<210> 270 <211> 12 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with acyl (AC)
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphthyl)Ala (D-2-Nal)
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = beta-(2-naphthyl)Ala (2-Nal)
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = beta-Ala or alpha-aminoisobutyric acid (Aib)
<220> <221> MOD_RES <222> (12)..(12) <223> AMIDATION
<400> 270
<210> 271 <211> 7 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(7) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Cys or homocyteine (hCys)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (7)..(7) <223> AMIDATION
<400> 271
<210> 272 <211> 7 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(7) <223> Cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Cys or homocysteine (hCys)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (7)..(7) <223> AMIDATION
<400> 272
<210> 273 <211> 7 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(7) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Lys, ornithine (Orn), 2,4-diaminobutyric acid (Dab), or 2,3-diaminopropionic acid (Dap)
<220> <221> MOD_RES <222> (7)..(7) <223> AMIDATION
<400> 273
<210> 274 <211> 6 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (1)..(6) <223> cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = His, 1-amino-1-cyclopropanecarboxylic acid (A3c), 1-amino-1cyclopentanecarboxylic acid (A5c), 1-amino-1-cyclohexanecarboxylic acid (A6c), 2-aminoindan-2-carboxylic acid (Aic), or Apc
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (6)..(6) <223> AMIDATION
<400> 274
<210> 275 <211> 6 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(6) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = His, 1-amino-1-cyclopropanecarboxylic acid (A3C), 1-amino-lcyclopentanecarboxylic acid (A5C), 1-amino-1-cyclohexanecarboxylic acid (A6C), 2-aminoindan-2-carboxylic acid (AiC), or ApC
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (6)..(6) <223> AMIDATION
<400> 275
<210> 276 <211> 7 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (1)..(7) <223> cyclic
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (7)..(7) <223> Xaa = Lys, ornithine (Orn), 2,4-diaminobutyric acid (Dab), or 2,3-diaminopropionic acid (Dap)
<220> <221> MOD_RES <222> (7)..(7) <223> AMIDATION
<400> 276
<210> 277 <211> 6 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(6) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (6)..(6) <223> AMIDATION
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = Lys or 2,3-diaminopropionic acid (Dap)
<400> 277
<210> 278 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Arg, norleucine (Nle), Gly, or D-Arg
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 278
<210> 279 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = norleucine (Nle), Gly, Ala, D-Ala, alpha-aminoisobutyric acid (Aib), Val, Ile, Leu, D-Arg, or Arg
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 279
<210> 280 <211> 9 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = norleucine (Nle) or Gly
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MISC_FEATURE <222> (9)..(9) <223> Xaa = penicillamine (Pen)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 280
<210> 281 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = norleucine (Nle) or Gly
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 281
<210> 282 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = D-Arg or Arg
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 282
<210> 283 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Ala, Val, or Gly
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = norleucine (Nle)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 283
<210> 284 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = 1-amino-1-cyclohexanecarboxylic acid (A6C), Gly, Ala, D-Ala, Val, Leu, beta-cyclohexylalanine (Cha), or alpha-aminoisobutyric acid (Aib)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = norleucine (Nle)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 284
<210> 285 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> xaa = D-Phe or D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 285
<210> 286 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe or D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 286
<210> 287 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Arg
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 287
<210> 288 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (2)..(2) <223> Xaa = D-Arg
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe or D-beta-(2-naphythyl)alanine (D-2-Nal)
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 288
<210> 289 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = norleucine (Nle)
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 289
<210> 290 <211> 8 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = norleucine (Nle), Ala, D-Ala, alpha-aminoisobutyric acid (Aib), Val, alpha-aminobutyric acid (Abu), Leu, Ile, beta-cyclohexylalanine (Cha), 1-amino-1-cyclohexanecarboxylic acid (A6C), Phe, or Gly
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MISC_FEATURE <222> (3)..(3) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 290
<210> 291 <211> 8 <212> PRT <213> Artificial sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (1)..(8) <223> cyclic
<220> <221> MOD_RES <222> (1)..(1) <223> modified with hydantoin(CO)
<220> <221> MISC_FEATURE <222> (5)..(5) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (8)..(8) <223> AMIDATION
<400> 291
<210> 292 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa = Tyr, beta-(2-naphthyl)alanine (2-Nal), beta-(1-naphthyl)alanine (1-Nal), Phe, Trp, (S)-pentatluorophenylalanine (Pff), or His, all modified with acyl group (AC)
<220> <221> DOMAIN <222> (3)..(9) <223> cylic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 292
<210> 293 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> Melanocortin receptor ligand to treat insulin sensitivity
<220> <221> DOMAIN <222> (3)..(9) <223> cyclic
<220> <221> MISC_FEATURE <222> (4)..(4) <223> Xaa = D-Ala
<220> <221> MISC_FEATURE <222> (6)..(6) <223> Xaa = D-Phe
<220> <221> MOD_RES <222> (9)..(9) <223> AMIDATION
<400> 293

Claims

A therapeutically effective amount of a melanocortin receptor 4 agonist for use in the treatment of insulin resistance in a subject by peripheral administration wherein said melanocortin receptor 4 agonist is:
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH₂; SEQ ID NO:50;
or a pharmaceutically acceptable salt thereof.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 1, wherein said subject is obese or overweight.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 1, wherein said subject is normal weight or lean.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 2 or 3, wherein said obese, overweight, normal weight or lean subject suffers from type II diabetes.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to any one of claims 1-4, wherein said peripheral administration is oral, subcutaneous, intraperitoneal, intramuscular, intravenous, rectal, transdermal or intranasal.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 5, wherein said administration is continuous, hourly, four times daily, three time daily, twice daily, once daily, once every other day, twice weekly, once weekly, once every two weeks, once a month, or once every two months.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 6, wherein said administration is continuous.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 6, wherein said administration is once daily.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 6, wherein said administration is once weekly
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 6, wherein said administration is once every two weeks.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to claim 6, wherein said administration is once a month or once every two months.
The therapeutically effective amount of a melanocortin receptor 4 agonist for use according to any one of claims 1-11, wherein said peripheral administration of an effective amount of a melanocortin receptor 4 agonist to treat said insulin resistance also reduces the body weight of said subject in need thereof.